Laboratory Monitoring for Patients on Lithium

Baseline Laboratory Tests

• The American Academy of Child and Adolescent Psychiatry recommends complete blood count, thyroid function tests (TSH, free T4), renal function tests (blood urea nitrogen, creatinine), serum calcium, urinalysis, and pregnancy test in females of reproductive age before starting lithium 1

Ongoing Monitoring Schedule

• The American Academy of Child and Adolescent Psychiatry recommends renal function tests, thyroid function tests, and urinalysis every 3-6 months, and serum calcium periodically (at least annually) 1

Special Monitoring Considerations

• The American Academy of Child and Adolescent Psychiatry suggests increasing monitoring frequency during intercurrent illness 2

Signs of Lithium Toxicity Requiring Immediate Testing

• Early signs of lithium toxicity include tremor, nausea, diarrhea, polyuria-polydipsia, according to Praxis Medical Insights 2

Laboratory Monitoring for Lithium Therapy

Serum Lithium Level Monitoring Schedule

• The American Academy of Sleep Medicine recommends checking serum lithium levels twice per week until both serum levels and clinical condition stabilize, with blood samples drawn 8-12 hours after the previous dose 3, 4
• Common adverse effects that warrant monitoring include subclinical hypothyroidism, which necessitates the regular thyroid function testing schedule, according to the American Academy of Sleep Medicine 3, 4

Lithium Therapy and Renal Function

Clinical Management Considerations

• The American Academy of Child and Adolescent Psychiatry recommends baseline urinalysis, blood urea nitrogen, and creatinine before starting lithium, and renal function tests and urinalysis should be monitored every 3-6 months once stable 5

Medication Interactions Affecting Renal Function

• The American Journal of Kidney Diseases advises that NSAIDs should be avoided in lithium-treated patients as they are contraindicated 6
• Lithium should be temporarily discontinued during serious intercurrent illness that increases AKI risk in patients with GFR <60 ml/min/1.73 m², as recommended by the American Journal of Kidney Diseases [7] [8]